Mechanisms of T-cell inhibition: implications for cancer immunotherapy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Vaccines

• Publication date

  2010-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/erv.09.144PMID 20021308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 3 study of immunotherapy to treat advanced prostate cancer

  2010cited by this paper
• NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

  2009cited by this paper
• Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1

  2009cited by this paper
• Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.

  2009cited by this paper
• Costimulatory and coinhibitory receptors in anti‐tumor immunity

  2009cited by this paper
• Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.

  2009cited by this paper
• CD28 and CTLA‐4 coreceptor expression and signal transduction

  2009cited by this paper
• Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1

  2009cited by this paper
• Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies

  2008cited by this paper
• Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?

  2008cited by this paper
• The tumor microenvironment and its role in promoting tumor growth

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

  2008cited by this paper
• Peripherally Induced Treg: Mode, Stability, and Role in Specific Tolerance

  2008cited by this paper
• Creating immune privilege: active local suppression that benefits friends, but protects foes

  2008cited by this paper
• Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding

  2008cited by this paper
• Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  2008cited by this paper
• Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

  2008cited by this paper
• T-regulatory cells in tumour-specific vaccination strategies.

  2008cited by this paper
• Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

  2008cited by this paper
• The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

  2008cited by this paper
• Creating immune privilege: active local suppression that benefits friends, but protects foes

  2008cited by this paper
• Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

  2008cited by this paper
• Phase I/II study of ipilimumab for patients with metastatic melanoma.

  2008cited by this paper
• Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1

  2007cited by this paper
• A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-β1 Mediates Suppression in the Tumor Microenvironment

  2007cited by this paper
• Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1

  2007cited by this paper
• Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells

  2007cited by this paper
• Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)

  2007cited by this paper
• Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

  2007cited by this paper
• Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

  2007cited by this paper
• The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance1

  2007cited by this paper
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

  2007cited by this paper
• FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis

  2007cited by this paper
• Regulatory T-cell development: is Foxp3 the decider?

  2007cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

  2007cited by this paper
• Reversal of Tumor-Mediated Immunosuppression

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.

  2007cited by this paper
• Checkpoint blockade in cancer immunotherapy.

  2007cited by this paper
• Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.

  2007cited by this paper
• CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

  2007cited by this paper
• PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata

  2007cited by this paper
• PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.

  2006cited by this paper
• Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer.

  2006cited by this paper
• FOXP3 controls regulatory T cell function through cooperation with NFAT.

  2006cited by this paper
• Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10

  2006cited by this paper
• CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine1

  2006cited by this paper
• A molecular perspective of CTLA-4 function.

  2006cited by this paper
• Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

  2006cited by this paper
• All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

  2006cited by this paper
• Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.

  2006cited by this paper
• Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

  2006cited by this paper
• Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

  2006cited by this paper
• Oral tolerance and TGF-beta-producing cells.

  2006cited by this paper
• Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans

  2006cited by this paper
• Regulatory T-cell compartmentalization and trafficking.

  2006cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

  2006cited by this paper
• Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

  2006cited by this paper
• Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

  2005cited by this paper
• Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells

  2005cited by this paper
• Human CD4+ regulatory T cells and activation-induced tolerance.

  2005cited by this paper
• Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

  2005cited by this paper
• Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1

  2005cited by this paper
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  2005cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

  2005cited by this paper
• Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo.

  2005cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Effector memory T cells, early metastasis, and survival in colorectal cancer.

  2005cited by this paper
• Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer

  2005cited by this paper
• Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells

  2005cited by this paper
• Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

  2005cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• In Vivo Instruction of Suppressor Commitment in Naive T Cells

  2004cited by this paper
• SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1

  2004cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• T cell anergy.

  2003cited by this paper
• Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.

  2003cited by this paper
• IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1

  2003cited by this paper
• Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

  2003cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Supporting Online Material

  2003cited by this paper

• Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.

  2024cites this paper
• Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression.

  2022cites this paper
• Neutrophil to Lymphocyte Ratio after Treatment Completion as a Potential Predictor of Survival in Patients with Triple-Negative Breast Cancer

  2021cites this paper
• Bone marrow‐derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD‐1/PD‐L1 pathway in multiple myeloma

  2020cites this paper
• Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

  2018cites this paper
• Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas.

  2018cites this paper
• Blocking Immunosuppressive Factors and Taking Advantage of the Nutrient Supply Within the Tumor Microenvironment: Pathways to Achieve Improved Cancer Immunotherapeutic Efficacy for Patients With Metastatic Melanoma

  2016cites this paper
• Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells

  2016cites this paper
• Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

  2015cites this paper
• Biomaterials in Regenerative Medicine and the Immune System

  2015cites this paper
• Biomaterial-Based Modulation of Cancer

  2015cites this paper
• Exhaustion T Cell + on Melanoma-Driven CD 8 with Herpes Simplex Virus Glycoprotein D The Effect of Adjuvanting Cancer Vaccines

  2014cites this paper
• Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice

  2014cites this paper
• Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression

  2014cites this paper
• The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion

  2014cites this paper
• Immune aspects of the breast tumor microenvironment.

  2013cites this paper
• Cancer vaccines: should we be targeting patients with less aggressive disease?

  2012cites this paper
• Immune response to sipuleucel-T in prostate cancer.

  2012cites this paper
• Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells

  2012cites this paper
• Harnessing DNA-induced immune responses for improving cancer vaccines

  2012cites this paper
• State of the Science: An Update on Renal Cell Carcinoma

  2012cites this paper
• Cellular Uptake of Neutrohpil Elastase Links Inflammation to Adaptive Immunity

  2012cites this paper
• Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.

  2011cites this paper
• Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials

  2011cites this paper
• Cancer Immunotherapy: Sipuleucel‐T and Beyond

  2011cites this paper
• Colorectal Cancer–Derived Foxp3+IL‐17+ T Cells Suppress Tumour‐Specific CD8+ T Cells

  2011cites this paper
• Is survivin the potential Achilles' heel of cancer?

  2011cites this paper
• CONTROLLING TRANSDUCTION AND REPLICATION OF ONCOLYTIC ADENOVIRUSES

  2010cites this paper
• CONTROLLING TRANSDUCTION AND REPLICATION OF ONCOLYTIC ADENOVIRUSES

  2010cites this paper
• GM-CSF-armed, replication-competent viruses for cancer.

  2010cites this paper